【出版时间及名称】：2010年1月韩国生物医药行业研究报告
        【作者】：WOORI证券
        【文件格式】：pdf
        【页数】：37
        【目录或简介】：
Table of contents
I. Investment Summary ...................................................................................................
II. Valuation......................................................................................................................
III. Healthcare to show high growth compared to other industries ............................
1. Healthcare market to post 2008~2013 CAGR of 13.2%
2. Focus on growth of IVD
3. Samsung and SK Chemical enter bio/healthcare
IV. Changing domestic and global diagnostics market ...............................................
1. Developed markets such as US, Europe leading global diagnostics industry
2. Domestic diagnostics overview
3. FDA approval to begin with 510k clearance
[Company Analysis]
Samsung Techwin (012450.KS, Buy, TP W120,000) ...................................................
SD (066930.KQ, Buy, TP W38,000) ...............................................................................
Macrogen (038290.KQ, Not Rated) ...............................................................................
Bioneer (064550.KQ, Not Rated) ..................................................................................
Infopia (036220.KQ, Not Rated) ....................................................................................
3
5
10
16
22
28
33
35
36